33 factorial design-based optimization of the formulation of nitrofurantoin microcapsules

Pharmacy World and Science

Volumn 18, Issue 1, 1996, Pages 20-25

  Karasulu, H Yeşim ^a   Ertan, Gökhan ^a   Günerï, Tamer ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

capsules; dissolution; drug compounding; factorial design; hydrogen ion concentration; nitrofurantoin; particle size

Indexed keywords

ALUMINUM SULFATE; CARBOXYMETHYLCELLULOSE; NITROFURANTOIN;

ARTICLE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; MICROENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY;

ALUM COMPOUNDS; ANTI-INFECTIVE AGENTS, URINARY; CARBOXYMETHYLCELLULOSE; DRUG COMPOUNDING; HYDROGEN-ION CONCENTRATION; KINETICS; MODELS, THEORETICAL; NITROFURANTOIN; PARTICLE SIZE; SOLUBILITY;

EID: 0029997335     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00449685     Document Type: Article

References (35)

1. Cadwallader DE, Jun HW. Nitrofurantoin. In: Folery K, editor. Analytical profiles of drug substances. New Jersey: Academic Press 1976;5:346-73.
2. Stoll RC, Bates TR, Swarbick J. In vitro dissolution and m vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates. J Pharm Sci 1973;62:65-8.
3. Bates TR, Young JM, Wu CM. pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules. J Pharm Sci 1974;63:643-5.
4. Remington's pharmaceutical sciences. 18th ed. Pennsylvania: Mack Publishing Company, 1990:1224.
5. Bennett WM, Singer I, Coggins CH. A practical guide to drug usage in adult patients with impaired renal function. JAMA 1970;214:1468-75.
6. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:272-4.
7. Lieberman HA, Lachman L. Pharmaceutical dosage forms. Vol. 2: Tablets. Part 6: Bioavailability in tablet technology. New York: Marcel Dekker, 1981:349-50.
8. Ertan G, Karasulu Y, Guneri T. Degradation and gastrointestinal stability of nitrofurantoin in acidic and alkaline media. Int J Pharm 1993;96:243-8.
9. Baichwal MR, Shetty UC. Studies on retardation of release of nitrofurantoin. Indian J Pharm Sci 1982;44:48-51.
10. Eldem T, Çapan Y. Formulation studies on sustained release nitrofurantoin tablets. Proceedings 3rd International Conference on Pharmaceutical Technology. Paris: APGI, 1983: 137-44.
11. Mendes TW, Masih SZ, Kanumurï RR. Effect of formulation and process variables on bioequivalency of nitrofurantoin I. J Pharm Sci 1978;67:1613-6.
12. Ertan G, Sangüllü I, Karasulu Y, Ercakir K, Gunerï T. Sustained release dosage form of nitrofurantoin Part 1. Preparation of microcapsules and in vitro release kinetics. J Microencapsulation 1994;11:127-35.
13. Karasulu HY, Ertan G, Güneri T, Pharmacokinetics and bioavailability of nitrofurantoin matrix tablets. In: Proceedings 5th European Congress Biopharmaceutics and Pharmacokinetics. Eur J Drug Metab Pharmacokinet 1993:108-14.
14. Paul HE, Hayes KJ, Paul MF, Borgmann AR. Laboratory studies with nitrofurantoin. J Pharm Sci 1967;56:882-5.
15. Lieberman HA, Lachman I, Schwarts JB. Pharmaceutical dosage forms. Vol. 2: Tablets. Part 3: Size reduction. New York: Marcel Dekker, 1990:110-11.
16. Fincher JH, Adams JG, Beal HM. Effect of particle size on gastrointestinal absorption of sulfisoxazole in dogs. J Pharm Sci 1965;54:704-8.
17. Ullah I, Cadwallader DE. Dissolution of slightly soluble powders under sink conditions II: Griseofulvin powders. J Pharm Sci 1971;60:230-3.
18. Brooke D. Dissolution profile of log normal powders: exact expression, J Pharm Sci 1971;62:795-8.
19. Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution I. J Pharm Sci 1972;61:1431-5.
20. Smallenbroek AJ, Bolhuijs GK, Lerk CF. The effect of particle size of disintegrants on the disintegration of tablets. Pharm Weekbl Sci 1981;3:172-5.
21. Oner L, Groves MJ. Optimization of conditions for preparing 2- to 5-micron-range gelatin microparticles by using chilled dehydration agents. Pharm Research 1993;10:621-6.
22. Farivar M, Kaş HS, Öner L, Hincal A. Factorial design-based optimization of the formulation of isosorbide-5-mononitrate microcapsules. J Microencapsulation 1993;10:309-17.
23. Vercammen PA, Néve RE. Interaction of povidone with aromatic compounds I: evaluation of complex formation by factorial analysis. J Pharm Sci 1980;69:1403-8.
24. Concheiro A, Vila-Jato JL, Martines-Pacheco R, Seijo B, Romos T. In vitro-in vivo correlation of eight nitrofurantoin tablet formulations: effect of various technological factors. Drug Dev Ind Pharm 1987;13:501-16.
25. Hixson AW, Crowel JH. Dependence of reaction velocity upon surface and agitation I. Theoretical consideration. Ind Eng Chem 1931 ;23:921-31.
26. Hixson AW, Crowel JH. Dependence of reaction velocity upon surface and agitation II. Experimental procedure in study of surface. Ind Eng chem 1931;23:1002-9.
27. Langenbucher F. Parametric representation of dissolution-rate curves by the RRSBW distribution. Pharm Ind 1976;38:472-7.
28. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 1972;24:979-81.
29. Hopfenberg HB. Controlled release from erodible slabs, cylinders and spheres. In: American Chemical Society Symposium on Controlled Release Polymeric Formulation; 1976 Apr; New York. New York: American Chemical Society.
30. United States Pharmacopeia XXII (USP XXII, NF XVII): Parkway, Rockville: Mack Printing Company, 1990:1788-9.
31. Banakar UV. Pharmaceutical dissolution testing. New York: Marcel Dekker, 1992:211.
32. Ertan G, Karasulu E, Abou-Nada M, Tosun M, Ȯzer A. Sustained release dosage form of nitrofurantoin Part II. In vivo urinary excretion in man. J Microencapsulation 1994;11:137-40.
33. Buzard JA, Conklin JD, O'Keefe E, Paul MF. Studies on the absorption distribution and elimination of nitrofurantoin in rat. J Pharmacol Exp Ther 1961;131:38A3.
34. Veronese M, Salvaterra M, Barzaghi D, Setnikar I. Urinary excretion in the rat of nifurpipone and of nitrofurantoin administered by different routes. Arzneimittelforsch (Drug Res) 1974;24:39-43.
35. Fassihi AR, Parkert MS, Pourkavoost N. Solid dispersion controlled release: effect of particle size, compression force and temperature. Drug Dev Ind Pharm 1985;11:523-35.